Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INMUNOVIR study of immune-guided CMV prevention in low-risk kidney transplantation
2025-520742-29-00Phase 3Authorised
- Sponsor
- Fundación para la Investigación Biomédica de Córdoba
- Start
- Dec 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of valganciclovir and ganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Fundación para la Investigación Biomédica de Córdoba. Primary endpoints: Incidence of CMV disease and Incidence of neutropenia by severity. Planned start Dec 2025; status: authorised.
02
Drugs
valganciclovirganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2025-520742-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520742-29-00.